Search Results - Cancer+Therapeutics

13 Results

Sort By:

Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells

Technology SummaryThe use of EGFR inhibitors in the treatment of NSCLC is well established, even being used as a first-line treatment for certain drugs like Gefitinib and Osimertinib. However, eventual drug-resistance by the tumor to these treatments remains a problem. This technology showcases how CRM1 inhibitor Leptomycin B can potentiate the EGFR...

Published: 9/17/2018 | Inventor(s): Weimin Gao, Zhongwei Liu

Keywords(s):

Category(s): Cancer Therapeutics

Disulfiram is a Direct and Potent Inhibitor of MGMT in Brain Tumor Cells

MGMT is a DNA repair protein that interferes with the cytotoxic action of alkylating chemotherapy agents. Because of the prevalence of this protein in tumors, especially brain tumors, there is a great need for the discovery of an inhibitor that will not harm bone marrow stem cells. This invention has solved this problem through the discovery of a...

Published: 12/13/2018 | Inventor(s): Kalkunte Srivenugopal, Ameya Paranjpe

Keywords(s):

Category(s): Cancer Therapeutics

Anticancer effects of Pimavanserin, a known anti-Parkinson drug

Cancer treatment methods must meet rigorous constraints before being approved by the FDA for administration to patients. Consequently, it is estimated that in 2012, more than 50% of the diagnosed cancer cases died worldwide due to these constraints preventing usage and treatment. It is becoming increasingly important to present more options for cancer...

Published: 12/17/2018 | Inventor(s): Sanjay Srivastava, Sharavan Ramachandran

Keywords(s):

Category(s): Cancer Therapeutics

Highly Selective AKR1C3 Inhibitors and Methods of Use Thereof

The enzyme, aldo-keto reductase family 1-member C (AKR1C3), is a well-known contributor to prostate cancer, acute myeloid leukemia, and chemotherapeutic resistance. However, current inhibition research has only identified compounds with an insufficient degree of selectivity for AKR1C3 over its other isoforms.This invention has established a method...

Published: 12/10/2018 | Inventor(s): Paul Trippier, Kshitij Verma, Trevor Penning, Tianzhu Zang

Keywords(s):

Category(s): Cancer Therapeutics

FDA approved Parkinson's Therapeutic Found Effectiive in Treatment of Cancer

Carbidopa is an FDA approved drug currently used in combination with Levo-Dopa to treat Parkinson’s disease. Carbidopa, itself, has no effect on Parkinson's patients, but by increasing the availability of Levo-dopa in the brain enhances the effectiveness of the drug in patients. As such, these two drugs are always prescribed together. Researchers...

Published: 12/10/2018 | Inventor(s): Vadivel Ganapathy, Yangzom Bhutia, Babu Ellappan, Sabarish Ramachandran

Keywords(s):

Category(s): Cancer Therapeutics, Pharmaceutical

Drug Combinations to Overcome Resistance to BRAF and MEK Inhibitors

The drug Vemurafenib is one of the few treatment options for late-stage melanoma currently available. However, upon either single or chronic treatment with Vemurafenib, the cancer cells develop mechanisms of resistance to the drug. Other drugs available in the market such as Mek1/2 inhibitors and BRAF inhibitors fail to overcome Vemurafenib resistance....

Published: 11/28/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria

Keywords(s):

Category(s): Cancer Therapeutics, Pharmaceutical, Therapeutics

Formulations (oral and topical cream) containing anti-cancer agents to prevent or treat melanoma

Melanoma is the most serious type of skin cancer and develops in the cells that produce melanin. Treatment for early-stage melanomas usually include surgery to remove the melanoma. If the melanoma has spread beyond the skin, treatment options may include surgery to remove affected lymph nodes and chemotherapy. An effective new drug delivery system...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria, Hussaini Qhattal

Keywords(s): Cancer, consumer products, Drug delivery, Pharmaceuticals, Therapeutics

Category(s): Therapeutics, Cancer Therapeutics, Plant Derivative

MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer

Breast cancer has become the most frequently diagnosed cancer in women, and is the second leading cause of death in women. Although relatively ineffective, Mouse Double Mouse Minute 2 (MDM2) inhibitors blocking the MDM2-p53-binding interphase are currently used for the treatment of advanced breast cancer. This new technology targets a novel direct inhibitor...

Published: 12/10/2018 | Inventor(s): Ruiwen Zhang

Keywords(s):

Category(s): Cancer Therapeutics, Therapeutics

Method to Enhance Treatment of Metastatic Melanoma with BRAF Inhibitors

Malignant melanoma is the most lethal form of skin cancer and accounts for almost 80% of skin cancer deaths. About 60% of melanomas have a mutation in the BRAF oncogene at V600E. The FDA recently approved (January 2014) the combination of a BRAF inhibitor (Dabrafenib) and a MEK 1/2 inhibitor (Trametinib) to treat this type of melanoma. A problem...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria

Keywords(s): Cancer, Medicine, Molecular Medicine, Therapeutics

Category(s): Cancer Therapeutics, Pharmaceutical, Therapeutics

Mechanism of the Ineffectiveness of Panabinostat against Pancreatic Cancer (Solid Malignancies) and Strategies to Increase its Efficacy

Emerging evidence suggests that histone deacetylase inhibitors (HDACi) play a significant role in cancer treatment by allowing for the expression of a tumor suppressant gene. However, the inventors have discovered that HDACi also up-regulates the expression of Bcl2 protein, which leads to resistance to chemotherapy in almost every tumor model. Therefore,...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Srinivas Boreddy

Keywords(s): Anti-inflammatory, Biomarker, Cancer, Gastrointestinal, integrin mediated cell signaling, nutraceuticals, Therapeutics

Category(s): Cancer Therapeutics

1 2